There is some residual anti coagulant, but the volume of blood transfused is relatively small and the systemic impact of this is very low. It is possible to remove anti coagulant by re-suspending the cells in saline after initial processing but this adds to the processing time. Current clinical studies have demonstrated that the presence of some anti coagulant in the processed blood does not impact on the patient. This is evident in a reduced blood loss in Hemosep treated patients compared to control.
Posted in: Hemosep